Business Context and Reporting Period
Company: Bullfrog AI Holdings, Inc. (BFRG)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Bullfrog AI is a digital biopharmaceutical company utilizing its proprietary AI/ML platform, bfLEAP®, to analyze complex clinical and preclinical data. The company aims to de-risk drug development, identify high-responder patient populations, and "rescue" failed drug assets for divestiture. Operations are conducted through its wholly-owned subsidiary, Bullfrog AI, Inc.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $65,000 |
| Net Loss | $(6,993,647) | $(5,355,869) |
| Operating Expenses | $7,236,383 | $5,427,324 |
| Cash and Cash Equivalents (Year-End) | $5,435,983 | $2,624,730 |
| Accumulated Deficit | $(16,793,556) | $(9,754,924) |
| Debt | $0 (No long-term debt) | $0 |
Note: The company had no long-term debt as of December 31, 2024. Current liabilities totaled $588,090, primarily accounts payable and accrued expenses.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to $0 in 2024 compared to $65,000 in 2023. The 2023 revenue was derived from a single commercial service contract; no revenue was recognized in 2024.
- Increased Operating Expenses: Total operating expenses rose 33% to $7.24 million.
- R&D Expenses: Increased 55% to $2.22 million, driven by hiring additional R&D staff, engaging disease experts, and initiating preclinical studies (specifically an siRNA obesity program).
- G&A Expenses: Increased 25% to $5.01 million, attributed to personnel costs, equity compensation, and recruiting fees.
- Financing Activity: The company raised approximately $8.4 million in net proceeds from equity issuances in 2024 (February and October offerings), compared to $8.6 million in 2023.
- Interest Income: Increased by approximately $77,000 due to higher average cash balances.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. As of December 31, 2024, cash reserves ($5.4 million) are insufficient to fund planned operations for at least one year beyond the filing date. The company requires additional financing or revenue to meet obligations.
- Recent Developments: In February 2025, the company announced a collaboration with Eleison Pharmaceuticals Inc. to apply its Bullfrog Data Networks® solution to analyze clinical data for a Phase III oncology trial.
- Internal Control Weaknesses: Management identified material weaknesses in internal controls over financial reporting as of December 31, 2024, which remain unremediated. These include a lack of proper documentation and implementation of effective internal controls.
- Strategic Focus: The company continues to pursue a strategy of generating revenue through strategic partnerships and acquiring rights to failed drugs to "rescue" them using AI analysis before divesting the assets.
- Liquidity Risk: The company relies on future equity sales, debt transactions, or licensing agreements to fund operations. There is no assurance that such funding will be available on acceptable terms.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $5.4 million cash balance against the projected burn rate given the 33% increase in operating expenses.
- Revenue Generation: Assess the timeline for monetizing the new Eleison Pharmaceuticals collaboration and other pipeline assets, given zero revenue in 2024.
- Internal Controls: Review the remediation plan for the material weaknesses in internal controls over financial reporting.
- License Obligations: Confirm the ability to meet minimum annual royalty payments (e.g., $300,000 to JHU-APL) without generating revenue.
- Dilution Risk: Evaluate the impact of potential future equity raises required to sustain operations on existing shareholders.